LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Massachusetts Institute of Technology
Headquarters:
Cambridge, MA, United States of America
Website:
http://web.mit.edu
Year Founded:
1861
Status:
Non-biopharma
Biopharma related deals can be found by searching the organization's name in the
Deals
Module.
BioCentury
|
Nov 27, 2024
Emerging Company Profile
Valora: Blocking cancer’s immune evasion via glycan targeting
San Diego-based company’s antibody-lectin chimeras act as molecular decoys to disrupt cellular interactions
Read More
BioCentury
|
Aug 3, 2024
Deals
Biotechs find problem-solving in academia, and mostly outside the big hubs
Academia-biotech deals span innovative assets to tissue bank resources to enabling technologies
Read More
BioCentury
|
Jul 25, 2024
Finance
Venture Report: Third Arc’s $165M series A; Brenig heads for clinic with $65M round
Plus: Flagship-backed Abiologics launches; and rounds for GRO, Autobahn and Rona
Read More
BioCentury
|
Apr 30, 2024
Distillery Therapeutics
Host SCGB1D2 for Lyme disease
Read More
BioCentury
|
Mar 16, 2024
Discovery & Translation
Science spotlight: Boosting immunotherapy by counteracting Tregs in tumor-draining lymph nodes and more
BioCentury’s roundup of translational innovations
Read More
BioCentury
|
Feb 24, 2024
Discovery & Translation
Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more
BioCentury’s roundup of translational innovations
Read More
BioCentury
|
Feb 21, 2024
Distillery Therapeutics
Increasing Kupffer cell GPR3 activation for obesity
Read More
BioCentury
|
Feb 9, 2024
Product Development
Getting the most out of digital endpoints: case studies from Verge’s CMO
Perspectives from Diego Cadavid on Verge’s digital-first Phase Ib strategy for ALS, and on building a pivotal endpoint using an Xbox sensor
Read More
BioCentury
|
Jan 6, 2024
Product Development
Flagship’s AI hub: making models that co-pioneer
The VC’s Pioneering Intelligence unit is experimenting with new methods, operationalizing tools, and creating companies
Read More
BioCentury
|
Dec 13, 2023
Finance
Dec. 12 Quick Takes: Targeted genomic DNA insertion company Tome launches with $213M
Plus: Bicara’s latest big round is a $165M series C, Shinobi launches, Pfizer readies to close Seagen deal and more
Read More
Items per page:
10
1 - 10 of 795